Neurological complications occur commonly in HIV infected patients and is seen in 20-40% of them. (3) In about 10% patients, the onset of the disease occurs with neurological symptoms. (3) The neurological damage by primary HIV infection is due to activation of microglial cells infected with HIV which in turn spreads the infection to the surrounding tissue. (4) However neurological damage in a case of HIV infection may also be due to opportunistic infections both viral and non viral. (5) There is also an increased incidence of cerebrovascular diseases in children with HIV infection possibly due to vascular immaturity as a contributing factor. (5) Studies have also shown that antiretroviral therapy (ART) and prophylaxis decreases the risk for neurological complications. (5) However continued neurological damage can occur in spite of vigorous antiretroviral therapy. (6) Combination ART effectively decreases the viral load however its poor penetration into the central nervous system (CNS) is responsible for “incomplete protection”. (7) Other than poor access of the drugs into the CNS the other possible hypothetical reasons proposed for the persistence of neurocognitive damages due to HIV even after initiation of ART include failure of antiretroviral agents to reverse neurological damage, chronic systemic immune activation associated with microbial translocation products, sustained CNS inflammation and the possible contribution from aging, amyloid deposition and other co-morbidities. (8) At a study carried out in the National Institute of Health, Bethesda it was observed that 2 out of 11 patients receiving ART with cerebrovascular lesions continued to have persistent viral multiplication. (5) Another study was carried out in Italy to predict the prevalence of neurological damage even after ART and its possible risk factor, it was found that persistent neuropschycolocial effects continued to persist in 62.8% of the patients and thus ART should be initiated as soon as any neurocognitive impairment is diagnosed so as to prevent any irreversible neurological damage. (9)
Thus it is necessary to screen all HIV infected individuals for any neurocognitive diseases and initiate highly active antiretroviral therapy (HAART) at the earliest to prevent any further neurological damage. This is extremely important since HIV associated neurological disorders continue to occur with “less advanced immunosuppression”. (8) Even after HAART has been implemented it is necessary to repeatedly screen the patients for any continued neurological damage.
References:
1) Shah I, Chudgar P. Antiphospholipid Syndrome in A Human Immunodeficiency Virus 1-Infected Child. Pediatr Infect Dis J. 2006 ; 25: 185-186
2) Shah I, Chilkar S. CMV Retinitis in an HIV infected Child with Undetectable Viral Load. Indian Pediatr. 2010; 47: 893
3) Miura Y, Kishida S.Neurological Complications with HIV Infection. Brain Nerve. 2013; 65: 275-81
4) Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nature Reviews Immunology. 2005; 5:69–81
5) Manji H, Miller R.The Neurology of HIV Infection. J Neurol Neurosurg Psychiatry. 2004; 75: i29-i35
6) Gomes da Silva MM. Neurologic complications of HIV in the HAART era: where are we? Braz J Infect Dis. 2012; 16: 373-378.
7) Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol. 2012; 18:388-99.
8) Tan IL, McArthur JC. HIV-associated neurological disorders: a guide to pharmacotherapy. CNS Drugs. 2012; 26: 123-134.
9) Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr. 2007; 45: 174-82.
| References : |
- Shah I, Chudgar P. Antiphospholipid Syndrome in A Human Immunodeficiency Virus 1-Infected Child. Pediatr Infect Dis J. 2006 ; 25: 185-186
- Shah I, Chilkar S. CMV Retinitis in an HIV infected Child with Undetectable Viral Load. Indian Pediatr. 2010; 47: 893
- Miura Y, Kishida S.Neurological Complications with HIV Infection. Brain Nerve. 2013; 65: 275-81
- Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nature Reviews Immunology. 2005; 5:69–81
- Manji H, Miller R.The Neurology of HIV Infection. J Neurol Neurosurg Psychiatry. 2004; 75: i29-i35
- Gomes da Silva MM. Neurologic complications of HIV in the HAART era: where are we? Braz J Infect Dis. 2012; 16: 373-378.
- Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol. 2012; 18:388-99.
- Tan IL, McArthur JC. HIV-associated neurological disorders: a guide to pharmacotherapy. CNS Drugs. 2012; 26: 123-134.
- Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr. 2007; 45: 174-82.
|